Coleman Robert E
Cancer Research Centre, Academic Unit of Clinical Oncology, Broomcross Building, Weston Park Hospital, Sheffield S10 2SJ, UK.
Cancer Treat Rev. 2006;32 Suppl 1:1-2. doi: 10.1016/s0305-7372(06)80001-0.
Patients with advanced cancer often develop bone metastases that lead to significant skeletal morbidity and substantially reduced functionality and autonomy [Coleman RE, Rubens RD. Bone metastases. In: Clinical Oncology, 2nd edn. New York: Churchill Livingstone. 2004, p. 1091-128]. As current methods of diagnosing bone metastases are cumbersome and not cost-effective, there is great interest in exploring the potential of biochemical assays that measure bone turnover activity. These markers may have value in measuring metastatic bone disease (MBD) progression and identifying patients at higher risk for metastases. Bone markers are also being evaluated as a possible guide to optimize treatment of bone complications. In the reports included in this supplement, experts at the frontiers of bone marker research offer insights on their progress.
晚期癌症患者常发生骨转移，导致严重的骨骼病变，并使功能和自主性大幅下降[科尔曼·R·E，鲁本斯·R·D。骨转移。见：《临床肿瘤学》，第2版。纽约：丘吉尔·利文斯通出版社。2004年，第1091 - 128页]。由于目前诊断骨转移的方法繁琐且不具成本效益，人们对探索测量骨转换活性的生化检测方法的潜力兴趣浓厚。这些标志物在测量转移性骨病（MBD）进展以及识别转移风险较高的患者方面可能具有价值。骨标志物也正在被评估为优化骨并发症治疗的可能指导。在本增刊所收录的报告中，骨标志物研究前沿的专家们介绍了他们的进展情况。
